The wearable cardioverter-defibrillator in a real-world clinical setting: experience in 102 consecutive patients

[1] Martens E(2014)Incidence of sudden cardiac death in Germany. Results from an emergency medical service registry in Lower Saxony Europace 12 369-381

[2] Sinner MF(2002)Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction N Engl J Med 346 877-883

[3] Siebermair J(2005)Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT): design and clinical protocol Ann Noninvasive Electrocardiol 10 34-43

[4] Raufhake C(2005)Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure N Engl J Med 352 225-237

[5] Beckmann BM(2012)Reduction in appropriate therapy and mortality through ICD programming N Engl J Med 367 2275-2283

[6] Veith S(2013)Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator Eur Heart J 34 2230-2242

[7] Düvel D(2010)Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival JACC 56 194-203

[8] Steinbeck G(2015)Use of the wearable cardioverter defibrillator in high-risk cardiac patients. Data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II Registry) Circulation 132 1613-1619

[9] Kääb S(2013)Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction JACC 62 2000-2007

[10] Moss AJ(2013)Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter-defibrillator Circ Arrhythm Electrophysiol 6 117-128

[1] Martens E(2014)Incidence of sudden cardiac death in Germany. Results from an emergency medical service registry in Lower Saxony Europace 12 369-381

[2] Sinner MF(2002)Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction N Engl J Med 346 877-883

[3] Siebermair J(2005)Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT): design and clinical protocol Ann Noninvasive Electrocardiol 10 34-43

[4] Raufhake C(2005)Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure N Engl J Med 352 225-237

[5] Beckmann BM(2012)Reduction in appropriate therapy and mortality through ICD programming N Engl J Med 367 2275-2283

[6] Veith S(2013)Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator Eur Heart J 34 2230-2242

[7] Düvel D(2010)Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival JACC 56 194-203

[8] Steinbeck G(2015)Use of the wearable cardioverter defibrillator in high-risk cardiac patients. Data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II Registry) Circulation 132 1613-1619

[9] Kääb S(2013)Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction JACC 62 2000-2007

[10] Moss AJ(2013)Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter-defibrillator Circ Arrhythm Electrophysiol 6 117-128